Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria
Status:
Recruiting
Trial end date:
2023-03-14
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the mechanism of action for ligelizumab (QGE031)
treatment in patients with chronic urticaria.
The study has two parts. The study population will consist of approximately 68 male and
female healthy volunteers and patients. In Part 1, approximately 20 healthy volunteers and
patients with chornic urticaria will be enrolled. In Part 2 approximately 48 patients with
chronic urticaria (spontaneous chronic urticaria, cholinergic urticaria or cold urticaria).
Part 1 consists of a screening period up 2 weeks and a visit with skin tests; there is no
treatment taken in Part 1. Part 2 is randomized, subject, investigator and sponsor blinded.
It consists of a screening period up to 4 weeks, a 16 week treatment period and a 12-week
follow-up period after last treatment. A follow-up call at Week 32 will be performed via
telephone.